# Pembrolizumab in Elderly Patients With Advanced Lung Cancer

> **NCT03293680** · PHASE2 · COMPLETED · sponsor: **Spanish Lung Cancer Group** · enrollment: 83 (actual)

## Conditions studied

- Non Small Cell Lung Cancer

## Interventions

- **DRUG:** Pembrolizumab

## Key facts

- **NCT ID:** NCT03293680
- **Lead sponsor:** Spanish Lung Cancer Group
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-01-15
- **Primary completion:** 2023-04-28
- **Final completion:** 2023-07-15
- **Target enrollment:** 83 (ACTUAL)
- **Last updated:** 2024-10-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03293680

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03293680, "Pembrolizumab in Elderly Patients With Advanced Lung Cancer". Retrieved via AI Analytics 2026-05-31 from https://api.ai-analytics.org/clinical/NCT03293680. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*